Hillstream BioPharma, Inc. – NASDAQ:HILS
Hillstream BioPharma stock price today
Hillstream BioPharma stock price monthly change
Hillstream BioPharma stock price quarterly change
Hillstream BioPharma stock price yearly change
Hillstream BioPharma key metrics
Market Cap | 4.17M |
Enterprise value | N/A |
P/E | -1.15 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 1.70 |
PEG ratio | N/A |
EPS | -142.6 |
Revenue | N/A |
EBITDA | -8.59M |
Income | -1.60B |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeHillstream BioPharma stock price history
Hillstream BioPharma stock forecast
Hillstream BioPharma financial statements
| Dec 2022 | 0 | -1.59B | |
|---|---|---|---|
| Mar 2023 | 0 | -2.66M | |
| Jun 2023 | 0 | -2.33M | |
| Sep 2023 | 0 | -1.82M |
| 2023-05-22 | 0.11 | 0.23 |
|---|---|---|
| 2023-08-11 | 0.16 | 0.16 |
| 2023-11-13 | -0.05 | -0.10524 |
| Dec 2022 | 6688628 | 1.14M | 17.12% |
|---|---|---|---|
| Mar 2023 | 4721926 | 1.52M | 32.21% |
| Jun 2023 | 4599408 | 1.53M | 33.27% |
| Sep 2023 | 3166951 | 1.41M | 44.52% |
| Dec 2022 | -1.06M | 0 | -22.46K |
|---|---|---|---|
| Mar 2023 | -3.46M | 0 | 523.36K |
| Jun 2023 | -1.51M | 0 | 1.84M |
| Sep 2023 | -908.96K | 0 | -306.00K |
Hillstream BioPharma alternative data
| Aug 2023 | 1 |
|---|---|
| Sep 2023 | 1 |
| Oct 2023 | 1 |
| Nov 2023 | 1 |
| Dec 2023 | 1 |
| Jan 2024 | 1 |
| Feb 2024 | 1 |
| Mar 2024 | 1 |
| Apr 2024 | 1 |
| May 2024 | 1 |
| Jun 2024 | 1 |
| Jul 2024 | 1 |
Hillstream BioPharma other data
| Period | Buy | Sel |
|---|---|---|
| Nov 2023 | 10000 | 0 |
| Dec 2023 | 29000 | 0 |
-
What's the price of Hillstream BioPharma stock today?
One share of Hillstream BioPharma stock can currently be purchased for approximately $0.23.
-
When is Hillstream BioPharma's next earnings date?
Unfortunately, Hillstream BioPharma's (HILS) next earnings date is currently unknown.
-
Does Hillstream BioPharma pay dividends?
No, Hillstream BioPharma does not pay dividends.
-
How much money does Hillstream BioPharma make?
Hillstream BioPharma has a market capitalization of 4.17M. Hillstream BioPharma made a loss 9.32M US dollars in net income (profit) last year or -$0.11 on an earnings per share basis.
-
What is Hillstream BioPharma's stock symbol?
Hillstream BioPharma, Inc. is traded on the NASDAQ under the ticker symbol "HILS".
-
What is Hillstream BioPharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Hillstream BioPharma?
Shares of Hillstream BioPharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Hillstream BioPharma have?
As Jul 2024, Hillstream BioPharma employs 1 workers.
-
When Hillstream BioPharma went public?
Hillstream BioPharma, Inc. is publicly traded company for more then 3 years since IPO on 12 Jan 2022.
-
What is Hillstream BioPharma's official website?
The official website for Hillstream BioPharma is hillstreambio.com.
-
Where are Hillstream BioPharma's headquarters?
Hillstream BioPharma is headquartered at 1200 Route 22 East, Bridgewater, NJ.
-
How can i contact Hillstream BioPharma?
Hillstream BioPharma's mailing address is 1200 Route 22 East, Bridgewater, NJ and company can be reached via phone at +90 89553140.
Hillstream BioPharma company profile:
Hillstream BioPharma, Inc.
hillstreambio.comNASDAQ
1
Biotechnology
Healthcare
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.
Bridgewater, NJ 08807
CIK: 0001861657
ISIN: US4327051011
CUSIP: 432705101
